This module uses fundamental data of Telomir Pharmaceuticals to approximate its Piotroski F score. Telomir Pharmaceuticals F Score is determined by combining nine binary scores representing 3 distinct fundamental categories of Telomir Pharmaceuticals Common. These three categories are profitability, efficiency, and funding. Some research analysts and sophisticated value traders use Piotroski F Score to find opportunities outside of the conventional market and financial statement analysis.They believe that some of the new information about Telomir Pharmaceuticals financial position does not get reflected in the current market share price suggesting a possibility of arbitrage. Check out Telomir Pharmaceuticals Altman Z Score, Telomir Pharmaceuticals Correlation, Telomir Pharmaceuticals Valuation, as well as analyze Telomir Pharmaceuticals Alpha and Beta and Telomir Pharmaceuticals Hype Analysis.
Telomir
Piotroski F Score
Change In Cash
Free Cash Flow
Change In Working Capital
Total Cash From Operating Activities
Issuance Of Capital Stock
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Total Assets
Total Current Liabilities
Total Stockholder Equity
Retained Earnings
Accounts Payable
Cash
Total Liab
Net Invested Capital
Total Current Assets
Net Working Capital
Selling General Administrative
Operating Income
Net Income From Continuing Ops
Research Development
Total Operating Expenses
Income Before Tax
Probability Of Bankruptcy
As of the 15th of June 2024, Net Debt is likely to drop to about 79.8 K. In addition to that, Short and Long Term Debt is likely to drop to about 80.8 K.
At this time, it appears that Telomir Pharmaceuticals' Piotroski F Score is Frail. Although some professional money managers and academia have recently criticized Piotroski F-Score model, we still consider it an effective method of predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
The critical factor to consider when applying the Piotroski F Score to Telomir Pharmaceuticals is to make sure Telomir is not a subject of accounting manipulations and runs a healthy internal audit department. So, if Telomir Pharmaceuticals' auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if Telomir Pharmaceuticals' financial numbers are properly reported.
One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to project the various growth rates. Understanding the correlation between Telomir Pharmaceuticals' different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Telomir Pharmaceuticals in a much-optimized way.
F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.
Total Assets
5.76 Million
At this time, Telomir Pharmaceuticals' Total Assets are very stable compared to the past year.
About Telomir Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Telomir Pharmaceuticals Common's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Telomir Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Telomir Pharmaceuticals Common based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Additional Information and Resources on Investing in Telomir Stock
When determining whether Telomir Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Telomir Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Telomir Pharmaceuticals Common Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Telomir Pharmaceuticals Common Stock:
You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Telomir Pharmaceuticals. If investors know Telomir will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Telomir Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Telomir Pharmaceuticals is measured differently than its book value, which is the value of Telomir that is recorded on the company's balance sheet. Investors also form their own opinion of Telomir Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Telomir Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Telomir Pharmaceuticals' market value can be influenced by many factors that don't directly affect Telomir Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Telomir Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Telomir Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Telomir Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.